The gift of 20.2% of outstanding shares to a new director with no disclosed compensation or purchase price is a severe ownership dilution event. Monitor for any subsequent insider selling by Zhou or Liu, and for any related party transactions or business changes that may follow this unusual board appointment.
Price Chart
Executive Summary
Goldenwell Biotech appointed Ming Zhou as a director on October 8, 2026, expanding the board to four members. In connection with the appointment, CEO Shuang Liu gifted Zhou 20,000,000 shares of common stock, representing approximately 20.2% of the outstanding shares. This massive share transfer to a new director with no prior relationship to the company is a highly unusual and potentially dilutive event for existing shareholders.
Key Facts
- Ming Zhou appointed as director on October 8, 2026.
- CEO Shuang Liu gifted 20,000,000 shares (approx. 20.2% of outstanding) to Zhou.
- Board now consists of four persons: Shuang Liu, Yang Lee, Hua Xie, and Ming Zhou.
- Zhou's background is in health products, nutritional supplements, and direct-sales in Thailand.
- No family relationships or prior transactions between Zhou and the company are disclosed.
Financial Impact
20,000,000 shares transferred, representing ~20.2% of outstanding common stock. No cash consideration disclosed.
Risk Factors
- Massive dilution to existing shareholders from the 20.2% share gift.
- Potential for future related-party transactions or asset transfers given the new director's background.
- Possible change in control or strategic direction without shareholder vote.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001477932-26-006138 |
| Document: 0001477932-26-006138-index-headers.html | 0001477932-26-006138 |
| Document: 0001477932-26-006138-index.html | 0001477932-26-006138 |
| Document: 0001477932-26-006138.txt | 0001477932-26-006138 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | SC 13D | $0.6897 | awaiting T+20 | — | $0.6500 (−5.76%) |
Oct 9, 2026 18d ago | 3 | $0.6897 | awaiting T+20 | — | $0.6500 (−5.76%) |
Oct 9, 2026 18d ago | 8-K | $0.6897 | awaiting T+20 | — | $0.6500 (+5.76%) |
Sep 29, 2026 28d ago | 8-K | $0.6897 $0.6500 | ▲ +5.76% | ▲ +6.42% | $0.6500 (+5.76%) |
Jun 29, 2026 17w ago | 10-Q/A | $0.5200 $0.9000 | ▼ −73.08% | ▼ −73.33% | $0.6500 (−25.00%) |
Jun 26, 2026 17w ago | 10-Q/A | $0.5200 $0.9000 | ▼ −73.08% | ▼ −73.33% | $0.6500 (−25.00%) |
Jun 26, 2026 17w ago | 10-Q/A | $0.5200 $0.9000 | ▼ −73.08% | ▼ −73.33% | $0.6500 (−25.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers